Apimeds Pharmaceuticals US (APUS) Non-Current Assets (2025)

Apimeds Pharmaceuticals US (APUS) posted Non-Current Assets of $150.2 million for Q4 2025, up 91525.52% on a QoQ basis from $163928.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Non-Current Assets (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Non-Current Assets history runs 1 years deep, the most recent figure standing at $150.2 million for Q4 2025.

Quarterly Non-Current Assets changed N/A year-over-year to $150.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $150.6 million (changed N/A YoY) and the FY2025 annual result came in at $150.2 million, changed N/A from the prior year.
Non-Current Assets was $150.2 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $163928.0 in the prior quarter.
Across five years, Non-Current Assets topped out at $150.2 million in Q4 2025 and bottomed at $163928.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	36.78 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	26.33 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	8.68 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	79.20 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	3.84 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	15.70 Bn
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	25.92 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	2.47 Bn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	9.64 Bn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	150.20 Mn

Download Data